PGⅠ/Ⅱ
ZECEN
DR1035/1036
| Quantity: | |
|---|---|
Gastric cancer, one of the digestive system malignant tumors, with the characteristic of both high prevalence and high mortality, has become one of the most common diseases which damage human’s health and safety.
The number of patients with gastric cancer is increasing, and because the symptom of early gastric cancer is not so obvious, many patients are diagnosed with elderly gastric cancer.With the significant progress of medical treatment in recent years, many clinical observations showed that early diagnosis and treatment can effectively rise patients’ 5 year survival rate and improve their prognosis. Therefore, exploring the monitoring indexes of gastric cancer is beneficial to the early diagnosis and treatment of patients with gastric cancer.
Now we mainly use pathological examination under gastroscope to diagnose gastric cancer, but as it is an invasive operation and some patients are impossible to tolerate the operation, so it has certain limits in early gastric cancer diagnosis.To further explore the practical value of Serum Pepsinogen I/II, gastrin-17 in diagnosis and prognosis of gastric cancer, we examined and analyzed the indexes mentioned above in patients with gastric ulcer, patients with gastric cancer, postoperative patients, and healthy people to provide theoretical reference for early diagnosis and prognosis of gastric cancer.
[INTENDED USE ]
The kit has been designed for the quantitative determination of Pepsinogen I/II (PGI/PGII) in human serum.
PGI range :1.0-350.0 ng/mL.
PGII range :0.5-150.0 ng/mL.
| Gastric Mucosa Function | PGⅠ | The product is used to quantitatively detect the content of pepsinogen Ⅰ (PGⅠ) in human serum in vitro, and clinically used to evaluate the function of oxyntic gland cells. Pepsinogen (PG) is the precursor of pepsin, which is secreted by gastric mucosa and converted into pepsin with the ability to decompose proteins. It is divided into two subgroups according to its biochemical properties and immunogenicity. The immunogenicity of components 1-5 is the same as PGⅠ, which is mainly secreted by chief cells of gastric glands and mucous neck cells, and components 6-7 are called PGⅡ, which is secreted by chief cells of oxyntic glands of gastric fundus mucosa of gastric corpus. The mucous neck cells of the acid glands, the mucous cells of the pyloric glands of the cardia and gastric antrum, and the Brunner glands of the upper duodenum can also produce PGⅡ, and the prostate and pancreas also produce a small amount of PGⅡ. Under normal circumstances, about 1% of PG enters the blood circulation, and the amount of entry is very stable. Therefore, serum PG I and II reflect the number of glands and cells in the gastric mucosa, and also indirectly reflect the secretion function of different parts of the gastric mucosa. When the gastric mucosa undergoes pathological changes, the serum PG content also changes. Known as a "serological biopsy" of the gastric mucosa. The development of Helicobacter pylori (Hp) infection to atrophic gastritis is accompanied by changes in pepsinogen, so this indicator is related to gastritis, Hp infection, gastric ulcer, gastric bleeding, etc. |
| PGⅡ | This product is used to quantitatively detect the content of pepsinogen II in human serum in vitro. Pepsinogen (PG) is the precursor of pepsin, which is secreted by gastric mucosa and converted into pepsin with the ability to decompose proteins. It is divided into two subgroups according to its biochemical properties and immunogenicity. The immunogenicity of components 1-5 is the same as PGⅠ, which is mainly secreted by chief cells of gastric glands and mucous neck cells, and components 6-7 are called PGⅡ, which is secreted by chief cells of oxyntic glands of gastric fundus mucosa of gastric corpus. The mucous neck cells of the acid glands, the mucous cells of the pyloric glands of the cardia and gastric antrum, and the Brunner glands of the upper duodenum can also produce PGⅡ, and the prostate and pancreas also produce a small amount of PGⅡ. Under normal circumstances, about 1% of PG enters the blood circulation, and the amount of entry is very stable. Therefore, serum PG I and II reflect the number of glands and cells in the gastric mucosa, and also indirectly reflect the secretion function of different parts of the gastric mucosa. When the gastric mucosa undergoes pathological changes, the serum PG content also changes. Known as a "serological biopsy" of the gastric mucosa. The development of Helicobacter pylori (Hp) infection to atrophic gastritis and then to gastric cancer is accompanied by changes in pepsinogen, so this indicator is related to gastritis, Hp infection, gastric ulcer, gastric bleeding, etc. The current clinical and laboratory determination methods of pepsinogen Ⅱ include enzyme-linked immunosorbent assay, colloidal gold method, fluorescence immunoassay, and chemiluminescence method. |
Gastric cancer, one of the digestive system malignant tumors, with the characteristic of both high prevalence and high mortality, has become one of the most common diseases which damage human’s health and safety.
The number of patients with gastric cancer is increasing, and because the symptom of early gastric cancer is not so obvious, many patients are diagnosed with elderly gastric cancer.With the significant progress of medical treatment in recent years, many clinical observations showed that early diagnosis and treatment can effectively rise patients’ 5 year survival rate and improve their prognosis. Therefore, exploring the monitoring indexes of gastric cancer is beneficial to the early diagnosis and treatment of patients with gastric cancer.
Now we mainly use pathological examination under gastroscope to diagnose gastric cancer, but as it is an invasive operation and some patients are impossible to tolerate the operation, so it has certain limits in early gastric cancer diagnosis.To further explore the practical value of Serum Pepsinogen I/II, gastrin-17 in diagnosis and prognosis of gastric cancer, we examined and analyzed the indexes mentioned above in patients with gastric ulcer, patients with gastric cancer, postoperative patients, and healthy people to provide theoretical reference for early diagnosis and prognosis of gastric cancer.
[INTENDED USE ]
The kit has been designed for the quantitative determination of Pepsinogen I/II (PGI/PGII) in human serum.
PGI range :1.0-350.0 ng/mL.
PGII range :0.5-150.0 ng/mL.
| Gastric Mucosa Function | PGⅠ | The product is used to quantitatively detect the content of pepsinogen Ⅰ (PGⅠ) in human serum in vitro, and clinically used to evaluate the function of oxyntic gland cells. Pepsinogen (PG) is the precursor of pepsin, which is secreted by gastric mucosa and converted into pepsin with the ability to decompose proteins. It is divided into two subgroups according to its biochemical properties and immunogenicity. The immunogenicity of components 1-5 is the same as PGⅠ, which is mainly secreted by chief cells of gastric glands and mucous neck cells, and components 6-7 are called PGⅡ, which is secreted by chief cells of oxyntic glands of gastric fundus mucosa of gastric corpus. The mucous neck cells of the acid glands, the mucous cells of the pyloric glands of the cardia and gastric antrum, and the Brunner glands of the upper duodenum can also produce PGⅡ, and the prostate and pancreas also produce a small amount of PGⅡ. Under normal circumstances, about 1% of PG enters the blood circulation, and the amount of entry is very stable. Therefore, serum PG I and II reflect the number of glands and cells in the gastric mucosa, and also indirectly reflect the secretion function of different parts of the gastric mucosa. When the gastric mucosa undergoes pathological changes, the serum PG content also changes. Known as a "serological biopsy" of the gastric mucosa. The development of Helicobacter pylori (Hp) infection to atrophic gastritis is accompanied by changes in pepsinogen, so this indicator is related to gastritis, Hp infection, gastric ulcer, gastric bleeding, etc. |
| PGⅡ | This product is used to quantitatively detect the content of pepsinogen II in human serum in vitro. Pepsinogen (PG) is the precursor of pepsin, which is secreted by gastric mucosa and converted into pepsin with the ability to decompose proteins. It is divided into two subgroups according to its biochemical properties and immunogenicity. The immunogenicity of components 1-5 is the same as PGⅠ, which is mainly secreted by chief cells of gastric glands and mucous neck cells, and components 6-7 are called PGⅡ, which is secreted by chief cells of oxyntic glands of gastric fundus mucosa of gastric corpus. The mucous neck cells of the acid glands, the mucous cells of the pyloric glands of the cardia and gastric antrum, and the Brunner glands of the upper duodenum can also produce PGⅡ, and the prostate and pancreas also produce a small amount of PGⅡ. Under normal circumstances, about 1% of PG enters the blood circulation, and the amount of entry is very stable. Therefore, serum PG I and II reflect the number of glands and cells in the gastric mucosa, and also indirectly reflect the secretion function of different parts of the gastric mucosa. When the gastric mucosa undergoes pathological changes, the serum PG content also changes. Known as a "serological biopsy" of the gastric mucosa. The development of Helicobacter pylori (Hp) infection to atrophic gastritis and then to gastric cancer is accompanied by changes in pepsinogen, so this indicator is related to gastritis, Hp infection, gastric ulcer, gastric bleeding, etc. The current clinical and laboratory determination methods of pepsinogen Ⅱ include enzyme-linked immunosorbent assay, colloidal gold method, fluorescence immunoassay, and chemiluminescence method. |
